QIAGEN and Shanghai Biochip Corp. Sign Collaboration Agreement

158
QIAGEN Asia to supply RNAi and related solutions to China’s premier provider for drug discovery and development services Shanghai, China, May 29, 2008 — QIAGEN today announced that it has been selected by Shanghai Biochip Corporation (SBC) as a primary partner to supply various small interfering RNA (siRNA) library sets. SBC will use these library sets for setting up the first siRNA high-throughput screening center in China.

QIAGEN Asia to supply RNAi and related solutions to China’s premier provider for drug discovery and development services Shanghai, China, May 29, 2008 — QIAGEN today announced that it has been selected by Shanghai Biochip Corporation (SBC) as a primary partner to supply various small interfering RNA (siRNA) library sets. SBC will use these library sets for setting up the first siRNA high-throughput screening center in China.

siRNAs are synthetic RNA assay molecules which have the ability to turn genes “on” and “off” (RNA interference, RNAi). They are used for functional gene analysis and thus play a major role in drug development. “We are very pleased that SBC has selected QIAGEN as its partner and primary siRNA supplier”, said Dr. Frauke Ehlert, General Manager of QIAGEN China/ HK. “SBC is one of China’s largest service providers and R&D centers for systems biology research and drug discovery.  This collaboration further expands QIAGEN’s position as a leading supplier of innovative solutions.”

Songmin Xie, the operation manager of the RNAi screening center, commented: “The sophisticated siRNA design, broad coverage of human gene families, and excellent technical support are the main reasons why SBC selected QIAGEN Asia as the supply partner for the siRNA library. In forging this partnership, the Shanghai Biochip Corporation gains access to the largest portfolio of siRNA sets as well as the most advanced design algorithm available. This, accompanied by a comprehensive support structure, equips SBC to accomplish their goals to provide customers cutting edge solutions for drug discovery and development.

About QIAGEN:
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. QIAGEN has developed and markets more than 500 consumable products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,700 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com

About SBC:
SBC is one of the largest biotech companies in China established in August 2001. The company owns a vast campus of greater than 400,000 square feet (about 10 acres), with research building space of over 200,000 square feet, located at Shanghai Zhangjiang Hi-Tech Park in Pudong. SBC has received investments totalling $45 million USD from government grants and 10 shareholders consisting of top VC groups, universities, research institutes, hospitals, and large biopharma in Shanghai.

Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers’ funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors’ products, market acceptance of QIAGEN’s new products and the integration of acquisitions of technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Contact:
Asia/ Pacific
Brendan Green
Phone:  +86 21 38653824
Email:   Brendan.Green@qiagen.com